Disentangling Conflicting Evidence on DPP-4 Inhibitors and Outcomes of COVID-19: Narrative Review and Meta-analysis

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2021 Jan 29

PMID 33512688

Citations 24

Authors

B M Bonora

A Avogaro

G P Fadini

Affiliations

Soon will be listed here.

Abstract

Background: The infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread all over the world, becoming pandemic. Several studies have shown that diabetes mellitus (DM) is an independent risk factor that increases mortality and other adverse outcomes of coronavirus disease-19 (COVID-19). Studies have suggested that SARS-CoV-2 may bind dipeptidyl peptidase-4 (DPP4) for entering cells of the respiratory tract. Besides, DPP4 takes part in immune system regulation. Thus, DPP-4 inhibitors (DPP4i) may play a role against COVID-19.

Methods: We focused on the impact of DPP4i treatment on COVID-19-related outcomes in people with DM. For this purpose, we conducted a systematic review and meta-analysis to summarize the existing evidence on this topic.

Results: Retrospective observational studies provide inconsistent results on the association between use of DPP4i and outcomes of COVID-19. While two studies reported significantly lower mortality rates among patients with DM who received DPP4i versus those who did not, a series of other studies showed no effect of DPP4i or even worse outcomes. A meta-analysis of 7 studies yielded a neutral estimate of the risk ratio of COVID-19-related mortality among users of DPP4i (0.81; 95% CI 0.57-1.15).

Conclusion: In the absence of randomized controlled trials, observational research available so far provides inconclusive results and insufficient evidence to recommend use of DPP4i against COVID-19.

Citing Articles

Insulin and Metformin Administration: Unravelling the Multifaceted Association with Mortality across Various Clinical Settings Considering Type 2 Diabetes Mellitus and COVID-19.

Lewandowski L, Bronowicka-Szydelko A, Rabczynski M, Bednarska-Chabowska D, Adamiec-Mroczek J, Doroszko A Biomedicines. 2024; 12(3).

PMID: 38540218 PMC: 10968012. DOI: 10.3390/biomedicines12030605.

Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study.

Jang H, Moon S, Jung J, Han K, Rhee E, Lee W Endocrinol Metab (Seoul). 2024; 39(3):479-488.

PMID: 38282452 PMC: 11220209. DOI: 10.3803/EnM.2023.1857.

The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study.

Greco S, Monda V, Valpiani G, Napoli N, Crespini C, Pieraccini F Biomedicines. 2023; 11(8).

PMID: 37626788 PMC: 10452157. DOI: 10.3390/biomedicines11082292.

COVID-19 Outcomes and Diabetes Mellitus: A Comprehensive Multicenter Prospective Cohort Study.

Akinosoglou K, Schinas G, Bletsa E, Bristianou M, Lanaras L, Michailides C Microorganisms. 2023; 11(6).

PMID: 37374918 PMC: 10300742. DOI: 10.3390/microorganisms11061416.

Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.

Nassar M, Abosheaishaa H, Singh A, Misra A, Bloomgarden Z J Diabetes. 2023; 15(2):86-96.

PMID: 36690377 PMC: 9934962. DOI: 10.1111/1753-0407.13359.

References

Rhee S, Lee J, Nam H, Kyoung D, Shin D, Kim D . Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19. Diabetes Metab J. 2021; 45(2):251-259. PMC: 8024148. DOI: 10.4093/dmj.2020.0206. View

Fadini G, Morieri M, Longato E, Avogaro A . Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020; 43(6):867-869. PMC: 7103097. DOI: 10.1007/s40618-020-01236-2. View

Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y . Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013; 500(7461):227-31. PMC: 7095341. DOI: 10.1038/nature12328. View

Kawasaki T, Chen W, Htwe Y, Tatsumi K, Dudek S . DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2018; 315(5):L834-L845. DOI: 10.1152/ajplung.00031.2018. View

Kathe N, Shah A, Said Q, Painter J . DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control Study. Diabetes Ther. 2017; 9(1):141-151. PMC: 5801239. DOI: 10.1007/s13300-017-0353-5. View

Perez-Belmonte L, Torres-Pena J, Lopez-Carmona M, Ayala-Gutierrez M, Fuentes-Jimenez F, Jorge Huerta L . Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med. 2020; 18(1):359. PMC: 7666969. DOI: 10.1186/s12916-020-01832-2. View

Gerstein H, McMurray J, Holman R . Real-world studies no substitute for RCTs in establishing efficacy. Lancet. 2019; 393(10168):210-211. DOI: 10.1016/S0140-6736(18)32840-X. View

Bonora E, Cataudella S, Marchesini G, Miccoli R, Vaccaro O, Fadini G . Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7383948. DOI: 10.1136/bmjdrc-2020-001191. View

Lambeir A, Durinx C, Scharpe S, De Meester I . Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003; 40(3):209-94. DOI: 10.1080/713609354. View

10.

Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-1034. PMC: 7270045. DOI: 10.1016/S0140-6736(20)30628-0. View

11.

Bonora E, Monami M, Bruno G, Zoppini G, Mannucci E . Attending Diabetes Clinics is associated with a lower all-cause mortality. A meta-analysis of observational studies performed in Italy. Nutr Metab Cardiovasc Dis. 2018; 28(5):431-435. DOI: 10.1016/j.numecd.2018.02.009. View

12.

Shao S, Xu Q, Yu X, Pan R, Chen Y . Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020; 209:107503. PMC: 7102585. DOI: 10.1016/j.pharmthera.2020.107503. View

13.

Bonora E, Cataudella S, Marchesini G, Miccoli R, Vaccaro O, Fadini G . A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory. Nutr Metab Cardiovasc Dis. 2020; 30(11):1945-1953. DOI: 10.1016/j.numecd.2020.08.018. View

14.

Sromova L, Busek P, Posova H, Potockova J, Skrha P, Andel M . The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016; 118:183-92. DOI: 10.1016/j.diabres.2016.06.020. View

15.

Liu X, Mei T, Chen W, Ye S . Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients. Mediators Inflamm. 2017; 2017:5032708. PMC: 5429949. DOI: 10.1155/2017/5032708. View

16.

Nafakhi H, Alareedh M, Al-Buthabhak K, Shaghee F, Nafakhi A, Kasim S . Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq. Diabetes Metab Syndr. 2020; 15(1):33-38. PMC: 7832757. DOI: 10.1016/j.dsx.2020.12.014. View

17.

Zhu L, She Z, Cheng X, Qin J, Zhang X, Cai J . Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020; 31(6):1068-1077.e3. PMC: 7252168. DOI: 10.1016/j.cmet.2020.04.021. View

18.

Nomoto H, Kimachi K, Miyoshi H, Kameda H, Cho K, Nakamura A . Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose. Endocr J. 2017; 64(4):417-424. DOI: 10.1507/endocrj.EJ16-0546. View

19.

Sesti G, Avogaro A, Belcastro S, Bonora B, Croci M, Daniele G . Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol. 2019; 56(6):605-617. DOI: 10.1007/s00592-018-1271-3. View

20.

Sainsbury C, Wang J, Gokhale K, Acosta-Mena D, Dhalla S, Byne N . Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study. Diabetes Obes Metab. 2020; 23(1):263-269. PMC: 7537530. DOI: 10.1111/dom.14203. View